På väg mot evidensbaserad terapi vid primär systemisk vaskulit. De senaste decenniernas framsteg har gett dagens patienter bättre läge
The prospects for patients suffering from systemic small vessel vasculitis have improved substantially in recent decades. The introduction of cyclophosphamide in the 1970s led to a dramatic improvement in survival rates. The discovery of ANCA meant a substantial increase in the number of detected cases, especially among elderly patients, as well as detection at an earlier stage of disease. At the
